ASMB — Assembly Biosciences Income Statement
0.000.00%
Last trade - 00:00- $571.00m
- $338.44m
- $28.52m
- 39
- 18
- 98
- 51
Annual income statement for Assembly Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 79.1 | 6.25 | 0 | 7.16 | 28.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 144 | 139 | 94.1 | 71.8 | 73.9 |
| Operating Profit | -64.8 | -133 | -94.1 | -64.6 | -45.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -62.2 | -132 | -93.1 | -61.2 | -39.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -62.2 | -130 | -93.1 | -61.2 | -40.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -62.2 | -130 | -93.1 | -61.2 | -40.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -62.2 | -130 | -93.1 | -61.2 | -40.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -19.1 | -28.7 | -22.8 | -13.4 | -6.69 |